信息搜索
你现在的位置：首页>教师信息>食品与制药工程学院食品与制药工程学院教师姓名：张发明
单 位食品与制药工程学院
职 称客座教授
学 历博士
E-mail
研究方向生物医药
详细描述张发明（1964-），男，博士，2009年湖北省首批“3551”人才计划特聘专家及2010年中组部“****“国家特聘专家。1987年毕业于武汉大学，获物理化学硕士学位；1990毕业于北京生物物理所生物化学专业，获博士学位。2002年在印第安纳大学获得MBA。2005至今在印第安纳大学生物化学系任副教授，研究蛋白质激酶结构，药物设计和Leptin（瘦素）信号转导通路课题。具有近30年生物医药的研发经验，特别是在蛋白质和基因工程药物研发方面卓有成就，有2篇文章以第一作者及通讯作者在《NATURE》上发表。发表研究论文21篇，发表论著5篇，7项药物设计及优化的美国专利。在美国EliLilly&Co.工作近12年，三次获得EliLilly&Co最高总裁奖。2013年6月被聘为湖北工业大学客座教授。
发表论文：
1.Rogers T, Li P, Smiley D, DiMarchi RD, and Zhang F., (2007), Design, synthesize and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun.63(7): 599–601.
2.Singh J, Ling L, Sawyer JS, Lee W, Zhang F, Yingling JM., (2005), Successful discovery of TbRI (ALK5) kinase inhibitors using HTS, target-hopping and virtual screening, Chemistry Today, 23 (3): 35-38.
3.Hamdouchi C, Zhong B, Mendoza J, Zhang F et al. (2005), Structure-Based Design of a New Class of Highly Selective Aminoimidazo[1,2-á]pyridine-Based Inhibitors of Cyclin Dependent Kinases, bioorganic & Medicinal Chemistry Letters. 15 (7): 1943-1947.
4.Jaramillo C, Zhang F. et al (2004), Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation, bioorganic & Medicinal Chemistry Letters. 14(24): 6095-6099.
5.J. Singh, J. Yingling, Zhang F, et al (2004), Transforming the TGF-a pathway: Convergence of distinct lead generation strategies on a novel kinase pharmcophroe for TbRI, Current Opinion in Drug Discovery and Development 7(4): 10-20.
6.Al-Awar RS, Ray JE, Zhang F. etal (2004). Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. Bioorg Med Chem Lett. 14(15): 3925-3928.
7.Sawyer JS, Beight DW, Zhang F, Yingling JM (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett. 14(13): 3581-3584.
8.Hadouchi C, Keyser H, Zhang F, Brooks H, et al (2004). The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo(1,2-a]pyridines. Molecular Cancer Therapeutics. 3(1):1-9.
9.Vincent J.-P, Johnson RB, Parsons S, Zhang F, Wang QM (2003). Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis. J. Virology. 77: 9020-9028.
10.Sanchez-Martinez C, Shih C, Zhu G, Dempsey JA, Zhang F (2003) . Studies on Cyclin Dependent Kinase Inhibitors:Indolo[2,3-a]pyrrolo[3,4-c]carbazoles versus Bis- indolylmaleimides, Bioorganic & Medicinal Chemistry Letters 13:3841-3846.
11.Vieth M, Brooks H, Hamdouchi C, McMillen W, Sawyer JS, Yingling J, and Zhang F(2003). Combining Medicinal Chemistry with Chemogenomic and Computer-Aided Structure-Based Design in Development of Novel Kinase Inhibitors, Cell. Mol. Biol. Lett 8 (2A):566-567.
12.Sawyer JS, Herron DK, Edward CR, Zhang F, and Yingling J (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-beta Type I Receptor Kinase Domain. Journal of Medicinal Chemistry 46 (19):3953-3956.
13.Wang QM, Hockman M, Staschke K, Zhang F, Parsons S (2002). Oligomerization and Cooperative RNA Synthesis Activity of HCV RNA-Dependent RNA Polymerase. J. Virology. 76:3865-3872
14.Jin L, Briggs S, Clawson D, Schevitz R, Smiley D, Tashjian A, Zhang F (2000). Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9 ? Resolution, J. Biol. Chem. 275: 27238-27244.
15.Zhang F, Basinski M, DiMarchi RD et al. (1997). Crystal Structure of the Obese Protein Leptin-E100, Nature. 387:206-209
16.Zhang J, Zhang F, Ebert D, Cobb MH, and Goldsmith EJ(1995). Activity of the MAP Kinase ERK2 is Controlled by a Flexible Surface Loop. Structure, 3:299-307.
17.Zhang F, Strand A, Robbins D, Cobb MH, and Goldsmith EJ (1994). Crystal Structure of MAP kinase ERK2 at 2.3? Resolution. Nature. 367: 704-711.
18.Zhang F, Robbins D, Cobb MH and Goldsmith EJ (1993), Crystallization and Preliminary X-ray Studies of Extracellular Signal-regulated Kinase-2/MAP kinase with an Incorporated His-tag. J. Mol.Biol. 233: 550-552.
19.Lin Z, Li J , Zhang F and Tsou C-L (1993), Structure of D-Glyceraldehyde-3-phosphate Dehydrogenase from Palinurus Versicolor Carrying the fluorescent NAD Derivatives at 2.7 ? Resolution. Arch. Biochem. Biophy. 302:161-166.
20.Zhang F, Kobe B, Stewart CB, Rutter W and Goldsmith EJ (1991). Structural Evolution of an Enzyme Specificity: The Structure of Rat Carboxypeptidase A2 at 1.9 ? Resolution. J. Biol. Chem. 266: 24606-24612.
出版论著:
1.Faming Zhang, John Beals, et al. (1997). “Obese Protein: Three-Dimensional Structure, Surface Properties, and Receptor-Binding Model”. in Leptin: The Voice of Adipose Tissue, W.F. Blum/W.Kiess/W.Rascher Eds. Edition J & J, 25-31.
2.Lei Jin, Armen Tashjian, and Faming Zhang (2003), “ Toward an Understanding of Human Parathyroid Hormone (PTH) Structure and Function”, in Parathyroid Hormone Molecular Biology, Tally Nareh/Justin Silver Eds. Landes Bioscience.
3.Faming Zhang, figure and text (21-23) contributions to college textbook “Fundamentals of Biochemistry”, 2/e by Voet and Pratt, John Wiley & Sons.
4.Faming Zhang, figure and text contributions to:” Growth Hormone Replacement Therapy in Adults with Hypopituitary Disease”. V1.1.
5.John Mayer, Faming Zhang, Richard DiMarchi (2007) “ Insulin Structure and Function” , Biopolymers, April 4.
专利:
1. EP**, WO**, Anti-obesity proteins
2. EP**, WO**, Protein crystals, their preparation and use
3. EP**, WO**, Crystalline parathyriod hormone
4. P13082, Aza-1,7 annulated carbazoles and Bisarylmaleimides as kinase inhibitors.
5. P13782, Reversed indolocarbazoles as CDK4 inhibitors.
6. US **, Parathyriod Hormone Formulation
7. US **, Methods and Compounds for Treating Proliferative Diseases.
8. NDA report 21-318. Forteo, Teriparatide injection: Chemistry, Manufacturing and Control (2000)
教育经历:
1990-1993德克萨斯大学西南医学中心，博士后
1987.9-1990.4北京生物物理所，生物化学， 博士学位
1984.9-1987.6武汉大学， 物理化学，硕士学位
1980.9-1984.7武汉大学， 化学，学士学位
2002年5月印第安那大学Kelly商学院，MBA
工作经历:
1989-1990日本PhotonFactory，访问学者
1990-1993德克萨斯大学西南医学中心，博士后
1993-1994德克萨斯大学西南医学中心，研究员
1994-2002EliLilly&Co.，高级科学家
2002-2005EliLilly&Co.，药物开发主管
2005-2008 印第安那大学（IndianaUniversity），副教授
2006-2007KinasiaBiopharmaceuticals,Inc.，总裁首席科学家
2007-2009中美冠科生物技术（北京）有限公司，总裁
2009-至今 中美华世通生物医药有限公司，董事长，CEO
2013-至今湖北工业大学，客座教授
学会会员：
2000年 LillyDiscoveryInformaticsCommittee
1999年-2000年LillyBiologyAcademicContactCommittee(BACC)Chair
1998年IBC5thInternationalSymposiumonObesityCo-Chair
1997年-1999年EliLillyGrantCommitteeforTechnologyToolbox
1999年-2002年EliLillyDueDiligence/ResearchAcquisitionteam
发表论文：
1.Rogers T, Li P, Smiley D, DiMarchi RD, and Zhang F., (2007), Design, synthesize and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun.63(7): 599–601.
2.Singh J, Ling L, Sawyer JS, Lee W, Zhang F, Yingling JM., (2005), Successful discovery of TbRI (ALK5) kinase inhibitors using HTS, target-hopping and virtual screening, Chemistry Today, 23 (3): 35-38.
3.Hamdouchi C, Zhong B, Mendoza J, Zhang F et al. (2005), Structure-Based Design of a New Class of Highly Selective Aminoimidazo[1,2-á]pyridine-Based Inhibitors of Cyclin Dependent Kinases, bioorganic & Medicinal Chemistry Letters. 15 (7): 1943-1947.
4.Jaramillo C, Zhang F. et al (2004), Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation, bioorganic & Medicinal Chemistry Letters. 14(24): 6095-6099.
5.J. Singh, J. Yingling, Zhang F, et al (2004), Transforming the TGF-a pathway: Convergence of distinct lead generation strategies on a novel kinase pharmcophroe for TbRI, Current Opinion in Drug Discovery and Development 7(4): 10-20.
6.Al-Awar RS, Ray JE, Zhang F. etal (2004). Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. Bioorg Med Chem Lett. 14(15): 3925-3928.
7.Sawyer JS, Beight DW, Zhang F, Yingling JM (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett. 14(13): 3581-3584.
8.Hadouchi C, Keyser H, Zhang F, Brooks H, et al (2004). The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo(1,2-a]pyridines. Molecular Cancer Therapeutics. 3(1):1-9.
9.Vincent J.-P, Johnson RB, Parsons S, Zhang F, Wang QM (2003). Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis. J. Virology. 77: 9020-9028.
10.Sanchez-Martinez C, Shih C, Zhu G, Dempsey JA, Zhang F (2003) . Studies on Cyclin Dependent Kinase Inhibitors:Indolo[2,3-a]pyrrolo[3,4-c]carbazoles versus Bis- indolylmaleimides, Bioorganic & Medicinal Chemistry Letters 13:3841-3846.
11.Vieth M, Brooks H, Hamdouchi C, McMillen W, Sawyer JS, Yingling J, and Zhang F(2003). Combining Medicinal Chemistry with Chemogenomic and Computer-Aided Structure-Based Design in Development of Novel Kinase Inhibitors, Cell. Mol. Biol. Lett 8 (2A):566-567.
12.Sawyer JS, Herron DK, Edward CR, Zhang F, and Yingling J (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-beta Type I Receptor Kinase Domain. Journal of Medicinal Chemistry 46 (19):3953-3956.
13.Wang QM, Hockman M, Staschke K, Zhang F, Parsons S (2002). Oligomerization and Cooperative RNA Synthesis Activity of HCV RNA-Dependent RNA Polymerase. J. Virology. 76:3865-3872
14.Jin L, Briggs S, Clawson D, Schevitz R, Smiley D, Tashjian A, Zhang F (2000). Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9 ? Resolution, J. Biol. Chem. 275: 27238-27244.
15.Zhang F, Basinski M, DiMarchi RD et al. (1997). Crystal Structure of the Obese Protein Leptin-E100, Nature. 387:206-209
16.Zhang J, Zhang F, Ebert D, Cobb MH, and Goldsmith EJ(1995). Activity of the MAP Kinase ERK2 is Controlled by a Flexible Surface Loop. Structure, 3:299-307.
17.Zhang F, Strand A, Robbins D, Cobb MH, and Goldsmith EJ (1994). Crystal Structure of MAP kinase ERK2 at 2.3? Resolution. Nature. 367: 704-711.
18.Zhang F, Robbins D, Cobb MH and Goldsmith EJ (1993), Crystallization and Preliminary X-ray Studies of Extracellular Signal-regulated Kinase-2/MAP kinase with an Incorporated His-tag. J. Mol.Biol. 233: 550-552.
19.Lin Z, Li J , Zhang F and Tsou C-L (1993), Structure of D-Glyceraldehyde-3-phosphate Dehydrogenase from Palinurus Versicolor Carrying the fluorescent NAD Derivatives at 2.7 ? Resolution. Arch. Biochem. Biophy. 302:161-166.
20.Zhang F, Kobe B, Stewart CB, Rutter W and Goldsmith EJ (1991). Structural Evolution of an Enzyme Specificity: The Structure of Rat Carboxypeptidase A2 at 1.9 ? Resolution. J. Biol. Chem. 266: 24606-24612.
出版论著:
1.Faming Zhang, John Beals, et al. (1997). “Obese Protein: Three-Dimensional Structure, Surface Properties, and Receptor-Binding Model”. in Leptin: The Voice of Adipose Tissue, W.F. Blum/W.Kiess/W.Rascher Eds. Edition J & J, 25-31.
2.Lei Jin, Armen Tashjian, and Faming Zhang (2003), “ Toward an Understanding of Human Parathyroid Hormone (PTH) Structure and Function”, in Parathyroid Hormone Molecular Biology, Tally Nareh/Justin Silver Eds. Landes Bioscience.
3.Faming Zhang, figure and text (21-23) contributions to college textbook “Fundamentals of Biochemistry”, 2/e by Voet and Pratt, John Wiley & Sons.
4.Faming Zhang, figure and text contributions to:” Growth Hormone Replacement Therapy in Adults with Hypopituitary Disease”. V1.1.
5.John Mayer, Faming Zhang, Richard DiMarchi (2007) “ Insulin Structure and Function” , Biopolymers, April 4.
专利:
1. EP**, WO**, Anti-obesity proteins
2. EP**, WO**, Protein crystals, their preparation and use
3. EP**, WO**, Crystalline parathyriod hormone
4. P13082, Aza-1,7 annulated carbazoles and Bisarylmaleimides as kinase inhibitors.
5. P13782, Reversed indolocarbazoles as CDK4 inhibitors.
6. US **, Parathyriod Hormone Formulation
7. US **, Methods and Compounds for Treating Proliferative Diseases.
8. NDA report 21-318. Forteo, Teriparatide injection: Chemistry, Manufacturing and Control (2000)
教育经历:
1990-1993德克萨斯大学西南医学中心，博士后
1987.9-1990.4北京生物物理所，生物化学， 博士学位
1984.9-1987.6武汉大学， 物理化学，硕士学位
1980.9-1984.7武汉大学， 化学，学士学位
2002年5月印第安那大学Kelly商学院，MBA
工作经历:
1989-1990日本PhotonFactory，访问学者
1990-1993德克萨斯大学西南医学中心，博士后
1993-1994德克萨斯大学西南医学中心，研究员
1994-2002EliLilly&Co.，高级科学家
2002-2005EliLilly&Co.，药物开发主管
2005-2008 印第安那大学（IndianaUniversity），副教授
2006-2007KinasiaBiopharmaceuticals,Inc.，总裁首席科学家
2007-2009中美冠科生物技术（北京）有限公司，总裁
2009-至今 中美华世通生物医药有限公司，董事长，CEO
2013-至今湖北工业大学，客座教授
学会会员：
2000年 LillyDiscoveryInformaticsCommittee
1999年-2000年LillyBiologyAcademicContactCommittee(BACC)Chair
1998年IBC5thInternationalSymposiumonObesityCo-Chair
1997年-1999年EliLillyGrantCommitteeforTechnologyToolbox
1999年-2002年EliLillyDueDiligence/ResearchAcquisitionteam
